International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 51
  • Journal CiteScore: 46.50
  • Journal Impact Factor: 26.99
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

Pharmacovigilance business continuity during COVID emergency: Italian case

Proceedings of Formulations 2021 & Pharmacovigilance 2021
September 15-16, 2021 WEBINAR

Francesca Rollo

Viatris company, Italy

Scientific Tracks Abstracts: Int J Drug Dev & Res


COVID-19 emergency started from China but the pandemic status was been defined after the “patient 0” identified in Italy. After the 25th February 2020 the situation of infection run fast and most of the company decided to close their offices and start the smartworking. The rapid change in the daily routine has an important impact on the socio-economic life but also for the pharmaceutical company. The pharmacovigilance department is deeply impacted by the COVID-19 emergency and the actions/decisions that have been taken should be effective and immediate. Aim of this speech is to present the approach of Italian pharmacovigilance team to the management of daily activities in order to ensure business continuity and pharmacovigilance requirements. In particular it will be describe how the Viatris Italian pharmacovigilance affiliate change the daily routine from the communication that the office are close and all employees started to work from home.

Biography :

Francesca Rollo is graduated in Biotechnology applied to Biomedical Research, he spent three years as a researcher in the field of pharmacology and toxicology at the Biogem research center. She has a master’s degree in regulatory activities and pharmaceutical technologies at the University of Pavia and from 2015 started as Pharmacovigilance and Regulatory Affairs support in Mylan Italia. Now, she is Deputy of Local Contact Point in Mylan Italia S.r.l a Viatris company where she coordinates and manages the pharmacovigilance for drugs, cosmetics, food supplements and medical devices, including the coordination of medical information activities.